Han Patriot
Registered Member
So when they can't win, they just block and create protectionism.
China committee eyes supply chain, biotech as Moolenaar takes helm
- Thread starter RabzonKhan
- Start date
冖_冖
Registered Member
Pentagon Names Biotech Firm WuXi AppTec to Chinese Military List
June 8, 2026 at 9:50 PM UTCThe Pentagon has named major pharmaceutical contractor WuXi AppTec Co. to a list of firms associated with the Chinese military, a move that could threaten its business and complicate research being done by American drugmakers.
WuXi AppTec, based in China, has performed various services for many of the world’s largest pharmaceutical companies, including drug discovery. As of 2024, WuXi was producing much of the active base ingredient used in Eli Lilly & Co.’s obesity drug Zepbound, Bloomberg has reported.
Pentagon adds tech giant Alibaba, electric car maker BYD to Chinese military list
The Pentagon has added several prominent Chinese businesses to its list of Chinese military companies
abcnews.com
Pentagon adds tech giant Alibaba, electric car maker BYD to Chinese military list
Being on the list prevents the companies from getting U.S. defense contracts.ByDIDI TANG Associated Press
June 8, 2026, 5:32 PM
WASHINGTON -- The Pentagon has added several prominent Chinese businesses, including the tech giant Alibaba, electric car maker BYD and search engine Baidu, to its list of Chinese military companies, preventing them from getting U.S. defense contracts.
The list, updated and published Monday by the Pentagon, now sanctions well-known, non-state-owned Chinese companies that are not traditionally considered to be in the defense or security sector.
Last edited:
冖_冖
Registered Member
Eli Lilly reunites with Abbisko in $1.9B, multiple target R&D pact
Eli Lilly has expanded its relationship with Abbisko Th | Eli Lilly has expanded its relationship with Abbisko Therapeutics, committing up to $1.9 billion to get the Chinese biotech to apply its drug discovery and early development capabilities to multiple targets.
Eli Lilly reunites with China's Abbisko in $1.9B, multiple target R&D pact
By Nick Paul Taylor Jun 24, 2026 7:47amEli Lilly has expanded its relationship with Abbisko Therapeutics, committing up to $1.9 billion to get the Chinese biotech to apply its drug discovery and early development capabilities to multiple targets.
Abbisko partnered with Lilly in 2022 to collaborate on a small molecule drug candidate. While Abbisko mainly focuses on cancer, the biotech describes (PDF) the P151 drug candidate co-owned with Lilly as a cardiometabolic program. The company’s in-house preclinical pipeline includes a GIPR obesity program and a STAT6 project focused on eczema and lung diseases, plus a slate of solid tumor candidates.
The expanded relationship broadens Lilly’s exposure to Abbisko’s capabilities, although details of what the companies will collaborate on are scarce. Abbisko will work on multiple targets chosen by Lilly. The partners have yet to disclose the targets or the therapeutic areas covered by the agreement.
Abbisko will perform discovery and early development work on programs against Lilly’s targets. Assigning those tasks to the Shanghai-based biotech positions Lilly to benefit from the fast pace of early development in China. Last month, Bristol Myers Squibb and Pfizer struck deals to funnel certain internal programs through the early development capabilities of Chinese partners.
Lilly is paying an undisclosed upfront fee to Abbisko. Beyond that, Abbisko is in line to receive up to $1.9 billion in development, regulatory and commercial milestones and tiered royalties on annual net sales.
The agreement continues the breakneck dealmaking pace set by Lilly, which has deep pockets because of the success of its GLP-1 drugs. In the past month, Lilly has struck deals to buy three vaccine developers for up to $3.8 billion and neuroscience startup 4E Therapeutics for an undisclosed amount, while inking licensing pacts with AlzeCure, Ascidian Therapeutics, Haisco Pharmaceutical and Hanmi Pharm.
Lilly is also in pole position to acquire capsid delivery, zinc finger and modular integrase platforms, plus a prion disease program. Sangamo is selling the assets as part of its bankruptcy process. Lilly is the stalking horse bidder for the assets.
冖_冖
Registered Member
Now hiring: Nvidia’s robotics team ramps up its China talent hunt
The US chip giant says it is recruiting for more than a dozen roles as it looks to move robots from research labs to real-world deployment.
www.scmp.com
Nvidia ramps up hiring for China robotics team, adding 12+ roles
Nvidia is hiring 12+ robotics and AI roles in China, partnering with Unitree Robotics, and expanding its workforce despite US-China export control tensions.
cryptobriefing.com
The chipmaker is doubling down on robotics and AI talent in China despite ongoing US export tensions
Nvidia ramps up hiring for China robotics team
Published: 9:30pm, 30 Jun 2026
US chip giant Nvidia is ramping up a talent drive for its robotics team in China, a market whose vendors account for the lion’s share of global shipments.
The Silicon Valley firm is recruiting for more than a dozen roles across Beijing, Shanghai and Shenzhen, according to a post on its official WeChat account on Monday. The positions span four key domains: embodied intelligence, simulation, implementation and solutions.
Nvidia said its robotics team planned to build a “leading robotics platform and ecosystem to help developers and companies create autonomous machines”, with the aim of accelerating the journey of robots from research labs into real-world deployment across various business scenarios.
冖_冖
Registered Member
Lawmakers propose bill to block sale of robots built in China
A bipartisan group of lawmakers introduced legislation to block the importation of robots made in China, as experts sound the alarm over security risks from advanced robots made by U.S. rivals.www.washingtontimes.com
Lawmakers propose bill to block sale of robots built in China
By Vaughn Cockayne - The Washington Times - Thursday, June 4, 2026
A bipartisan group of lawmakers introduced legislation to block the importation of robots made in China, as experts sound the alarm over security risks from advanced robots made by U.S. rivals.
The Guarding the U.S. Against Adversarial Robotics Dominance (GUARD) Act would require national security agencies to begin a review process for any humanoid and quadruped robots made by China or other countries.
The legislation was introduced on Wednesday by Republican Reps. John Moolenaar of Michigan and Jay Obernolte of California and Democratic Rep. Jennifer McClellan of Virginia.
Last year, Mr. Moolenaar and every other member of the U.S. House Select Committee on China sent a letter to the Trump administration demanding that Unitree be added to the Pentagon’s 1260H Chinese military companies list, the Department of Commerce Bureau of Industry and Security (BIS) Entity List and the FCC’s Covered List to better reflect its potential security risks to U.S. companies.
The legislation comes as U.S. robotics manufacturers face an uphill battle in competing with Chinese companies. Beijing currently controls roughly 89% of the world’s critical minerals used in the production of advanced robots, meaning U.S. firms heavily rely on Chinese supply chains for their manufacturing needs.
“The GUARD Act is a commonsense step towards protecting our national security, supporting American robotics companies, and ensuring the United States leads in the next generation of trusted robotics technology,” Mr. Obernolte wrote in the release.
Published Mon, Jun 1 20261:00 AM EDTUpdated Mon, Jun 1 20261:45 AM EDT
Nvidia picks Unitree for humanoid robot platform as Chinese startup eyes IPO
The U.S. chipmaker's first publicly available humanoid robotics system will use humanoids from Chinese startup Unitree.www.cnbc.com
Nvidia is working with Chinese startup Unitree for a research-focused humanoid robotics system
Nvidia has selected Chinese humanoid robot maker Unitree for the first robotics system the U.S. chipmaker is selling to researchers from Stanford to ETH Zurich, the company announced Monday.
The system combines Unitree’s nearly 6-foot-tall H2 humanoid robot with Nvidia’s Jetson Thor hardware, which includes the company’s advanced Blackwell GPU for on-device artificial intelligence capabilities.
Now hiring: Nvidia’s robotics team ramps up its China talent hunt
The US chip giant says it is recruiting for more than a dozen roles as it looks to move robots from research labs to real-world deployment.
Nvidia ramps up hiring for China robotics team, adding 12+ roles
Nvidia is hiring 12+ robotics and AI roles in China, partnering with Unitree Robotics, and expanding its workforce despite US-China export control tensions.
The chipmaker is doubling down on robotics and AI talent in China despite ongoing US export tensions
Nvidia ramps up hiring for China robotics team
Published: 9:30pm, 30 Jun 2026
US chip giant Nvidia is ramping up a talent drive for its robotics team in China, a market whose vendors account for the lion’s share of global shipments.
The Silicon Valley firm is recruiting for more than a dozen roles across Beijing, Shanghai and Shenzhen, according to a post on its official WeChat account on Monday. The positions span four key domains: embodied intelligence, simulation, implementation and solutions.
Nvidia said its robotics team planned to build a “leading robotics platform and ecosystem to help developers and companies create autonomous machines”, with the aim of accelerating the journey of robots from research labs into real-world deployment across various business scenarios.
US must innovate faster to counter China’s tech rise, lawmakers told
Witnesses urge investment in AI, robotics and chips, warning US research cuts risk eroding America’s technological edge.
www.scmp.com
US must innovate faster to counter China’s tech rise, lawmakers told
Witnesses urge investment in AI, robotics and chips, warning US research cuts risk eroding America’s technological edge
Published: 6:37am, 1 Jul 2026
A US congressional hearing on Tuesday urged the United States to innovate faster, smarter and better to counter China’s growing technological muscle, even as several lawmakers slammed the US President Donald Trump administration for policies they said undercut US national interests.
The testimony before the House Committee on Energy and Commerce comes as the two economic giants increasingly and aggressively face off over standards, economic models and supply chains, despite last month’s summit between Trump and Chinese President Xi Jinping aimed at easing tensions.
“At this very moment, China has overtaken the United States in total R&D spending, while the administration has cancelled or frozen more than 7,800 research grants,” said Kathy Castor, a Democrat from Florida. “Even more concerning, our scientists are leaving our labs and increasingly out of the country.”
Lawmakers and witnesses called for passage of several key pieces of legislation aimed at addressing funding, support and guardrails for a range of technologies and supply chains from artificial intelligence and advanced robotics to quantum computing and semiconductors.
But passage of legislation is hardly a magic bullet if the US does not implement those laws and if it continues to undercut its own strengths, witnesses said.
Over 1,700 AI bills were introduced across America’s 50 states regulating AI, witnesses said, which can lead to a hodgepodge of inconsistent rules and incentives.
“We can pass everything on this list, but if we keep starving our labs, then we’re just naming technologies for China to implement,” Castor said.
Some 22 per cent of US labs had rescinded offers to students, staff and postdoctoral researchers, according to studies, while 53 per cent had advised their students to seek further education outside the US.
Other indications of slipping US momentum cited: the European Research Council has seen a fourfold increase in applications from Americans seeking advanced grants, while international graduate student enrolments declined in 2025 to levels below any single year since the pandemic.
“We’re sort of going the wrong way,” said Jedidah Isler, chief science officer with the Federation of American Scientists. “Other competitors aren’t waiting. China is the most dramatic example, but India, South Korea, and the EU are all accelerating investments in this academic market.”
Witnesses noted the disquieting lead that China has taken in several technologies, especially advanced robotics, and the rapid progress it is making in open AI models and semiconductors.
冖_冖
Registered Member
How a ‘Chinese heart’ could get US blood pumping despite biotech decoupling
The BrioVAD pump is the first implantable device from China to receive approval for clinical trials in America.
www.scmp.com
How a ‘Chinese heart’ could get US blood pumping despite biotech decoupling
The BrioVAD pump is the first implantable device from China to receive approval for clinical trials in America
Published: 6:00pm, 1 Jul 2026
A “Chinese heart” could be helping to save lives in the United States despite efforts to decouple the two countries’ biotechnology sectors as a result of rising political tensions.
The fully magnetically levitated pump, which is slightly bigger than a table tennis ball, has been fitted to more than 100 patients with advanced heart failure across the United States as part of a nationwide clinical trial.
The BrioVAD is a left ventricular assist device (LVAD) that helps pump oxygen-rich blood to the rest of the body when the heart becomes too weak to do so.
In 2024, it became the first active implantable medical device from China to receive Food and Drug Administration approval for clinical trials in the US.
In a paper published last August, the trial team said that the trials were “designed to evaluate the safety and efficacy of the BrioVAD by demonstrating non-inferiority to HeartMate 3”.
The HeartMate 3 manufactured by Abbott is currently the only commercially available LVAD in the US.
By April, more than three-quarters of the top 30 US hospitals by volume for artificial heart implants had joined the trial, according to Science and Technology Daily.
The registry ClinicalTrials.gov, run by the US National Library of Medicine, shows that the study has 37 locations, including Emory University in Atlanta, Georgia, which performed the first operation in the US to implant the device.
